ZYBT Jilin Zhengye Biotechnology: Earnings per share for the trailing year

Official company branding of Zhengye Corp (ZYBT)

This daily price chart for Zhengye Biotechnology (ZYBT) on GURU.Markets reflects EPS dynamics, which currently stand at -256.20. The business relies on complex PRC certification and strict biolaboratory controls, which block new entrants. Zhengye Biotechnology (ZYBT) develops veterinary drugs utilizing government subsidies and exclusive patents. High safety requirements and lengthy licensing periods create a robust defensive barrier.

ZYBT jlzybio.com Earnings per share for the last twelve months (11/23/2025 - 11/18/2026)

Financial and market metric breakdowns for Zhengye Bio (ZYBT)

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:ZYBT, Zhengye Biotechnology Co., Ltd.
Product sample of Jilin Zhengye Biotechnology

This indicator serves as a filter to weed out speculative assets and stress-test capital resilience. The metric measures the dynamics of net profit per share over a rolling year, reflecting the efficiency of margin management and the pace of business scaling. By analyzing the 12-month YoY EPS history, an investor can discern the actual ability of Zhengye Biotechnology (ZYBT) to monetize R&D expenditures. Amid agricultural cyclicality and epidemiological risks, the volatility of the curve indicates the vulnerability of the company's profits.